Skip to content
Vakona.
Vakona.

Press release -

New acne medicine takes one step closer to market launch

Umeå-based pharmaceutical company Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine.

“Production is at a level of quality that enables the medicine to be used in human clinical trials. If all goes well the medicine should be on the market within five to seven years”, says Mats Strömqvist, CEO and Chairman of the Board of Vakona.

Vakona is developing a new, antibiotic-free treatment for acne. The company has worked for several years with a natural bacterial protein identified by Oleg Alexeyev's research group at Umeå University that can be used as an effective treatment for acne, for example by application as a skin cream.

“We have already tested our treatment in both in vivo and in vitromodels. After the remaining preclinical tests have been completed the next step is to start clinical development. With this agreement, we will obtain a production process allowing to produce the substance according to the quality standards required for clinical trials. If we see, which we confidently predict, a positive effect of our medicine on patients, we will be in a position to either sell the project to a pharmaceutical company in about three years from now or develop the medicine one step further ourselves”, says Mats Strömqvist.

Acne vulgaris is the most common skin disease in the world and affects more than 80 percent of all teenagers and young adults. Today's treatments still have many shortcomings, including long treatment times, unwanted side effects and poor results.

“Our concept enables patients to avoid the severe side effects and lengthy waits for noticeable results that treatments today often involve. Our medicine has properties that achieve results faster, and there is no indication that it causes any unwanted side effects either”, says Vakona’s founder, Oleg Alexeyev.

GTP Tech, a GTP Bioways company, will develop the industrial process to move on from the preclinical phase towards the manufacturing of the antibiotic-free treatment for clinics. “We are thrilled to support this project. Our experienced team will develop the process by end of 2022, allowing Vakona to meet its deadlines”, says Eric Devic, founder and director of GTP Tech.

“This agreement is a big step forward for us. We have a completely unique product for the treatment of acne, and hopefully patients will soon be able to benefit from it”, says Oleg Alexeyev.

For further information, please contact:

Mats Strömqvist, CEO, Vakona

+46 76 110 36 83

mats.stromqvist@vakona.se

Related links

Subjects

Categories


Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Press contacts

Elin Olsson

Press contact Head of PR and Communications PR and Communications +46706125561

Related content

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Umeå Biotech Incubator
Tvistevägen 48C
907 36 Umeå
Sweden
Visit our other newsrooms